Mission: The Bioanalytical Laboratory (BL) is a heavily used shared resource of the Comprehensive Cancer Center with a mission to provide access to advanced analytical services, technologies and scientific consultation for DNA, protein, and lipid chemistry. The BL specializes in discovery, identification, characterization, and quantification of biomolecules including: structural analysis of proteins, peptides and lipids by mass spectrometry and biochemical methods;DNA sequence analysis;DNA/RNA synthesis; chromatography of proteins, peptides, DNA, and lipids;and quantification of clinical biomarkers in tissue and blood specimens. Assets: Assets of the BL include more than 10 major instrument systems and the expertise of its staff members. Co-directors, Drs. Mark Lively and Michael Thomas, are expert chemists with more than 50 years of combined experience in research and core laboratory management. Dr. Thomas is a lipid mass spectrometry expert. Dr. Lively is a founding member and former president of the Association of Biomolecular Resource Facilities (ABRF). He is a member of the National Advisory Research Resources Council of the NIH National Center for Research Resources. The BL technicians have more than 80 years of combined laboratory experience. Usage: The BL supported the research of 73 Center members from 11/2009 -10/2010, analyzing 10,234 samples. The most heavily used services were: mass spectrometry methods (4,018 spls);DNA sequencing (4,299 spIs);biomarker HPLC (746 spIs);protein/peptide methods (248 spIs);and DNA synthesis (182 spIs). Center members received 60% of the services performed. Future directions: The BL recently added two important new mass spectrometers, a ThermoFisher TSQ Discovery Max electrospray, triple quadrupole mass spectrometer, to enhance the study of polar lipids and a ThermoFisher TSQ Quantum XLS triple quadrupole gas-chromatograph (GC) mass spectrometer. An Advion Nanomate? source was acquired for the Q-TOF mass spectrometer for proteomics. These instruments permit the BL to provide new and improved MS services of lipids, proteins, and peptides. Clinical biomarker analysis services will be expanded to enhance support of ongoing clinical studies.

Public Health Relevance

The BL is widely used by Center investigators from each program: 15 from Cell Growth and Survival;13 from Cellular Damage and Defense;and 7 from the Clinical Research Program. BL services provide specialized technologies to identify and characterize biological molecules to enable understanding their roles in basic biochemical mechanisms of cancer, cell proliferation, cell signaling, and DNA damage. The central availability of these shared resources insures availability, stability, reliability, and quality control.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wake Forest University Health Sciences
United States
Zip Code
Feliz-Mosquea, Yismeilin R; Christensen, Ashley A; Wilson, Adam S et al. (2018) Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Res Treat 172:69-82
Holmila, Reetta J; Vance, Stephen A; Chen, Xiaofei et al. (2018) Mitochondria-targeted Probes for Imaging Protein Sulfenylation. Sci Rep 8:6635
Rego, Stephen L; Harvey, Scott; Simpson, Sean R et al. (2018) TREX1 D18N mice fail to process erythroblast DNA resulting in inflammation and dysfunctional erythropoiesis. Autoimmunity :1-12
Li, X C; Wang, M Y; Yang, M et al. (2018) A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann Oncol 29:938-944
Godwin, Ryan C; Macnamara, Lindsay M; Alexander, Rebecca W et al. (2018) Structure and Dynamics of tRNAMet Containing Core Substitutions. ACS Omega 3:10668-10678
Lu, Yong; Wang, Qiang; Xue, Gang et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell 33:1048-1060.e7
Akter, Salma; Fu, Ling; Jung, Youngeun et al. (2018) Chemical proteomics reveals new targets of cysteine sulfinic acid reductase. Nat Chem Biol 14:995-1004
Peak, Taylor C; Praharaj, Prakash P; Panigrahi, Gati K et al. (2018) Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells. Biochem Biophys Res Commun 499:1004-1010
Chmielewski, Jeffrey P; Bowlby, Sarah C; Wheeler, Frances B et al. (2018) CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Mol Cancer Res 16:1687-1700
Han, Fei; Li, Chien-Feng; Cai, Zhen et al. (2018) The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun 9:4728

Showing the most recent 10 out of 548 publications